{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T04:20:14Z","timestamp":1770438014268,"version":"3.49.0"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-03204-3","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T09:59:53Z","timestamp":1766743193000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nanovaccines in hepatocellular carcinoma: a new frontier in cancer immunotherapy"],"prefix":"10.1007","volume":"43","author":[{"given":"Afreen","family":"Usmani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohd Aftab","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuradha","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rania I.M.","family":"Almoselhy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ambreen","family":"Shoaib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirunalini","family":"Gobinath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohd Nazam","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"key":"3204_CR1","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.jhep.2024.10.031","volume":"82","author":"EY Tan","year":"2025","unstructured":"Tan EY, Danpanichkul P, Yong JN, Yu Z, Tan DJ, Lim WH, et al. Liver cancer in 2021: global burden of disease study. J Hepatol. 2025;82:851\u201360. https:\/\/doi.org\/10.1016\/j.jhep.2024.10.031.","journal-title":"J Hepatol"},{"key":"3204_CR2","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3350\/cmh.2024.0835","volume":"31","author":"P Danpanichkul","year":"2025","unstructured":"Danpanichkul P, D\u00edaz LA, Suparan K, Tothanarungroj P, Sirimangklanurak S, Auttapracha T, et al. Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000\u20132021. Clin Mol Hepatol. 2025;31:525\u201347. https:\/\/doi.org\/10.3350\/cmh.2024.0835.","journal-title":"Clin Mol Hepatol"},{"key":"3204_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"3204_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease\u2014Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73\u201384. https:\/\/doi.org\/10.1002\/hep.28431.","journal-title":"Hepatology"},{"key":"3204_CR5","doi-asserted-by":"publisher","first-page":"3842","DOI":"10.3390\/cancers14163842","volume":"14","author":"X Fang","year":"2022","unstructured":"Fang X, Lan H, Jin K, Gong D, Qian J. Nanovaccines for cancer prevention and immunotherapy: an update review. Cancers. 2022;14:3842. https:\/\/doi.org\/10.3390\/cancers14163842.","journal-title":"Cancers"},{"key":"3204_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.puhe.2025.02.028","volume":"242","author":"Y Gu","year":"2025","unstructured":"Gu Y, Guo C, Liu Z, Zhang Y, Han X, Zhang X, Zhao S, Wang H, Zhang T. The trend in incidence of non-alcoholic fatty liver disease and its impact on cirrhosis and liver cancer: an analysis from global burden of disease 2021. Public Health. 2025;242:79\u201386.","journal-title":"Public Health"},{"key":"3204_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2024.101474","author":"A Yelsangikar","year":"2024","unstructured":"Yelsangikar A, Patil PS. Redefining HCC surveillance in india: A call for innovative and inclusive strategies. J Clin Exp Hepatol. 2024. https:\/\/doi.org\/10.1016\/j.jceh.2024.101474. [Epub ahead of print]:101474.","journal-title":"J Clin Exp Hepatol"},{"key":"3204_CR8","doi-asserted-by":"publisher","first-page":"101447","DOI":"10.1016\/j.jceh.2024.101447","volume":"14","author":"S Giri","year":"2024","unstructured":"Giri S, Singh A. Epidemiology of hepatocellular carcinoma in India \u2013 An updated review for 2024. J Clin Exp Hepatol. 2024;14:101447. https:\/\/doi.org\/10.1016\/j.jceh.2024.101447.","journal-title":"J Clin Exp Hepatol"},{"key":"3204_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4103\/ijmr.ijmr_1456_17","volume":"149","author":"E Dhamija","year":"2019","unstructured":"Dhamija E, Paul SB, Kedia S. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: an increasing concern. Indian J Med Res. 2019;149:9\u201317. https:\/\/doi.org\/10.4103\/ijmr.ijmr_1456_17.","journal-title":"Indian J Med Res"},{"key":"3204_CR10","doi-asserted-by":"publisher","first-page":"e2200118","DOI":"10.1200\/GO.22.00118","volume":"8","author":"VV Shetty","year":"2022","unstructured":"Shetty VV, Kellarai A. Comprehensive review of hepatocellular carcinoma in india: current challenges and future directions. JCO Glob Oncol. 2022;8:e2200118. https:\/\/doi.org\/10.1200\/GO.22.00118.","journal-title":"JCO Glob Oncol"},{"key":"3204_CR11","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1200\/JCO.2025.43.4_suppl.525","volume":"43","author":"S Naz","year":"2025","unstructured":"Naz S, Shaikh A, Alasadi M, Zhang HC. Mortality trends and Racial disparities in hepatocellular carcinoma associated with metabolic syndrome in the united States and texas: A 21-year analysis (1999\u20132020) using CDC WONDER database. J Clin Oncol. 2025;43:525. https:\/\/doi.org\/10.1200\/JCO.2025.43.4_suppl.525.","journal-title":"J Clin Oncol"},{"key":"3204_CR12","doi-asserted-by":"publisher","first-page":"k2817","DOI":"10.1136\/bmj.k2817","volume":"362","author":"EB Tapper","year":"2018","unstructured":"Tapper EB, Parikh ND. Mortality due to cirrhosis and liver cancer in the united States, 1999\u20132016: observational study. BMJ. 2018;362:k2817. https:\/\/doi.org\/10.1136\/bmj.k2817.","journal-title":"BMJ"},{"key":"3204_CR13","volume-title":"Cancer tomorrow: estimated number of new cases in 2040, liver cancer, both sexes, all ages","author":"International Agency for Research on Cancer","year":"2023","unstructured":"International Agency for Research on Cancer. Cancer tomorrow: estimated number of new cases in 2040, liver cancer, both sexes, all ages. Lyon: IARC; 2023."},{"key":"3204_CR14","doi-asserted-by":"publisher","first-page":"397","DOI":"10.25259\/ijmr_1729_23","volume":"160","author":"M Kalita","year":"2024","unstructured":"Kalita M, Devaraja M, Saha I, Chakrabarti A. Global burden of cancer pattern in 2020 & prediction to 2040 among older adults. Indian J Med Res. 2024;160:397. https:\/\/doi.org\/10.25259\/ijmr_1729_23.","journal-title":"Indian J Med Res"},{"key":"3204_CR15","volume-title":"Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Geneva: WHO; 2022."},{"key":"3204_CR16","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","volume":"386","author":"A Schweitzer","year":"2015","unstructured":"Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(15)61412-X.","journal-title":"Lancet"},{"key":"3204_CR17","doi-asserted-by":"publisher","first-page":"103","DOI":"10.17998\/jlc.2022.09.08","volume":"22","author":"EJ Choi","year":"2022","unstructured":"Choi EJ, Kim YJ. Liquid biopsy for early detection and therapeutic monitoring of hepatocellular carcinoma. J Liver Cancer. 2022;22:103\u201314. https:\/\/doi.org\/10.17998\/jlc.2022.09.08.","journal-title":"J Liver Cancer"},{"key":"3204_CR18","doi-asserted-by":"publisher","first-page":"175628482093173","DOI":"10.1177\/1756284820931734","volume":"13","author":"BJ Beudeker","year":"2020","unstructured":"Beudeker BJ, Boonstra A. Circulating biomarkers for early detection of hepatocellular carcinoma. Ther Adv Gastroenterol. 2020;13:1756284820931734. https:\/\/doi.org\/10.1177\/1756284820931734.","journal-title":"Ther Adv Gastroenterol"},{"key":"3204_CR19","doi-asserted-by":"publisher","first-page":"e2223504","DOI":"10.1001\/jamanetworkopen.2022.23504","volume":"5","author":"ND Parikh","year":"2022","unstructured":"Parikh ND, Tayob N, Al-Jarrah T, Kramer J, Melcher J, Smith D, et al. Barriers to surveillance for hepatocellular carcinoma in a multicenter cohort. JAMA Netw Open. 2022;5:e2223504. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.23504.","journal-title":"JAMA Netw Open"},{"key":"3204_CR20","doi-asserted-by":"publisher","first-page":"6106","DOI":"10.1186\/s12967-025-06106-0","volume":"23","author":"M Zhou","year":"2025","unstructured":"Zhou M, Zhou Z, Hu L, Chen S, Meng F, Chen J, et al. Multiplex immunohistochemistry to explore the tumor immune microenvironment in HCC patients with different GPC3 expression. J Transl Med. 2025;23:6106. https:\/\/doi.org\/10.1186\/s12967-025-06106-0.","journal-title":"J Transl Med"},{"issue":"4","key":"3204_CR21","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41575-019-0240-9","volume":"17","author":"B Chen","year":"2020","unstructured":"Chen B, Garmire L, Calvisi DF, Chua MS, Kelley RK, Chen X. Harnessing big \u2018omics\u2019 data and AI for drug discovery in hepatocellular carcinoma. Nat Reviews Gastroenterol Hepatol. 2020;17(4):238\u201351.","journal-title":"Nat Reviews Gastroenterol Hepatol"},{"key":"3204_CR22","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3390\/cancers15030817","volume":"15","author":"C Campani","year":"2023","unstructured":"Campani C, Zucman-Rossi J, Nault JC. Genetics of hepatocellular carcinoma: from tumor to Circulating DNA. Cancers. 2023;15:817. https:\/\/doi.org\/10.3390\/cancers15030817.","journal-title":"Cancers"},{"key":"3204_CR23","doi-asserted-by":"publisher","first-page":"1489649","DOI":"10.3389\/fimmu.2024.1489649","volume":"15","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Wei S, Xu M, Wu X, Dou W, Li H, et al. CAR-T cell therapy for hepatocellular carcinoma: current trends and challenges. Front Immunol. 2024;15:1489649. https:\/\/doi.org\/10.3389\/fimmu.2024.1489649.","journal-title":"Front Immunol"},{"key":"3204_CR24","doi-asserted-by":"publisher","first-page":"1326097","DOI":"10.3389\/fimmu.2023.1326097","volume":"14","author":"R Qin","year":"2023","unstructured":"Qin R, Jin T, Xu F. Biomarkers predicting the efficacy of immune checkpoint inhibitors in hepatocellular carcinoma. Front Immunol. 2023;14:1326097. https:\/\/doi.org\/10.3389\/fimmu.2023.1326097.","journal-title":"Front Immunol"},{"key":"3204_CR25","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1007\/s12672-025-01747-5","volume":"16","author":"M Zhang","year":"2025","unstructured":"Zhang M, Huang KL, Yin Q, Wu X, Zhu M, Li M. Spatial heterogeneity of the hepatocellular carcinoma microenvironment determines the efficacy of immunotherapy. Discov Oncol. 2025;16:1747. https:\/\/doi.org\/10.1007\/s12672-025-01747-5.","journal-title":"Discov Oncol"},{"key":"3204_CR26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12967-020-02697-y","volume":"19","author":"Z Liu","year":"2021","unstructured":"Liu Z, Zhang Y, Shi C, Zhou X, Xu K, Jiao D, et al. A novel immune classification reveals distinct immune escape mechanism and genomic alterations: implications for immunotherapy in hepatocellular carcinoma. J Transl Med. 2021;19:5. https:\/\/doi.org\/10.1186\/s12967-020-02697-y.","journal-title":"J Transl Med"},{"key":"3204_CR27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40164-025-00636-5","volume":"14","author":"J Tong","year":"2025","unstructured":"Tong J, Tan Y, Ouyang W, Chang H. Targeting immune checkpoints in hepatocellular carcinoma therapy: toward combination strategies with curative potential. Exp Hematol Oncol. 2025;14:65. https:\/\/doi.org\/10.1186\/s40164-025-00636-5.","journal-title":"Exp Hematol Oncol"},{"key":"3204_CR28","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.3390\/cancers13123091","volume":"13","author":"C Laface","year":"2021","unstructured":"Laface C, Laforgia M, Molinari P, Ugenti I, Gadaleta CD, Porta C, et al. Hepatic Arterial infusion of chemotherapy for advanced hepatobiliary cancers: state of the Art. Cancers (Basel). 2021;13:3091. https:\/\/doi.org\/10.3390\/cancers13123091.","journal-title":"Cancers (Basel)"},{"key":"3204_CR29","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1097\/CM9.0000000000003264","volume":"137","author":"Q Li","year":"2024","unstructured":"Li Q, Ding C, Cao M, Yang F, Yan X, He S, et al. Global epidemiology of liver cancer 2022: an emphasis on geographic disparities. Chin Med J (Engl). 2024;137:2334\u201342. https:\/\/doi.org\/10.1097\/CM9.0000000000003264.","journal-title":"Chin Med J (Engl)"},{"key":"3204_CR30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.21037\/tgh-24-91","volume":"10","author":"S Li","year":"2025","unstructured":"Li S, Zhou ZF, Long HJ, Yin JX, Wang HZ, Zhao JF. Multimodal combination regimen for a patient with advanced huge hepatocellular carcinoma: A case report. Transl Gastroenterol Hepatol. 2025;10:17. https:\/\/doi.org\/10.21037\/tgh-24-91.","journal-title":"Transl Gastroenterol Hepatol"},{"key":"3204_CR31","doi-asserted-by":"publisher","first-page":"e0290644","DOI":"10.1371\/journal.pone.0290644","volume":"18","author":"Z Tan","year":"2023","unstructured":"Tan Z, Zhang J, Xu L, Wang H, Mao X, Zou R, et al. Triple combination of HAIC-FO plus tyrosine kinase inhibitors and immune checkpoint inhibitors for advanced hepatocellular carcinoma: A systematic review and meta-analysis. PLoS ONE. 2023;18:e0290644. https:\/\/doi.org\/10.1371\/journal.pone.0290644.","journal-title":"PLoS ONE"},{"key":"3204_CR32","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","volume":"400","author":"A Vogel","year":"2022","unstructured":"Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400:1345\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(22)01200-4.","journal-title":"Lancet"},{"key":"3204_CR33","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1159\/000502755","volume":"8","author":"M Kudo","year":"2019","unstructured":"Kudo M. Scientific rationale for combination immunotherapy of hepatocellular carcinoma with anti-PD-1\/PD-L1 and anti-CTLA-4 antibodies. Liver Cancer. 2019;8:413\u201326. https:\/\/doi.org\/10.1159\/000502755.","journal-title":"Liver Cancer"},{"key":"3204_CR34","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1586\/14760584.6.5.797","volume":"6","author":"M Singh","year":"2007","unstructured":"Singh M, Chakrapani A, O\u2019Hagan D. Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev Vaccines. 2007;6:797\u2013808. https:\/\/doi.org\/10.1586\/14760584.6.5.797.","journal-title":"Expert Rev Vaccines"},{"key":"3204_CR35","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/nmat3753","volume":"12","author":"DJ Irvine","year":"2015","unstructured":"Irvine DJ, Swartz MA, Szeto GL. Engineering synthetic vaccines using cues from natural immunity. Nat Mater. 2015;12:978\u201390. https:\/\/doi.org\/10.1038\/nmat3753.","journal-title":"Nat Mater"},{"key":"3204_CR36","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3390\/nano15020122","volume":"15","author":"C Chen","year":"2025","unstructured":"Chen C, Xu YP, Meng H, Bao H, Hu Y, Li C, et al. Nano-oncologic vaccine for boosting cancer immunotherapy: the horizons in cancer treatment. Nanomaterials. 2025;15:122. https:\/\/doi.org\/10.3390\/nano15020122.","journal-title":"Nanomaterials"},{"key":"3204_CR37","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jconrel.2023.02.016","volume":"356","author":"Y Chen","year":"2023","unstructured":"Chen Y. Nanotechnology for next-generation cancer immunotherapy: state of the Art and future perspectives. J Control Release. 2023;356:14\u201325. https:\/\/doi.org\/10.1016\/j.jconrel.2023.02.016.","journal-title":"J Control Release"},{"key":"3204_CR38","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nnano.2013.237","volume":"9","author":"K Perica","year":"2014","unstructured":"Perica K, Tu A, Richter A, Bieler JG, Edidin M, Schneck JP. Magnetic field-induced T cell activation with nanoparticles for adoptive immunotherapy. Nat Nanotechnol. 2014;9:47\u201355. https:\/\/doi.org\/10.1038\/nnano.2013.237.","journal-title":"Nat Nanotechnol"},{"key":"3204_CR39","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0169-409X(97)00048-3","volume":"28","author":"JM Anderson","year":"1997","unstructured":"Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev. 1997;28:5\u201324. https:\/\/doi.org\/10.1016\/S0169-409X(97)00048-3.","journal-title":"Adv Drug Deliv Rev"},{"key":"3204_CR40","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1002\/adma.201200446","volume":"24","author":"JJ Moon","year":"2012","unstructured":"Moon JJ, Suh H, Irvine DJ. Engineering nano- and microparticles to tune immunity. Adv Mater. 2012;24:3724\u201346. https:\/\/doi.org\/10.1002\/adma.201200446.","journal-title":"Adv Mater"},{"key":"3204_CR41","doi-asserted-by":"publisher","unstructured":"Gholap AD, Khuspe PR, Faiyazuddin M, Uddin MJ, Bhowmik DD, Said RP, Sonawane KS, Parit S, Hatvate NT. Lipid-based vaccines against viruses including COVID-19. InLipids in pulmonary drug delivery , Academic Press. 2025;409\u201333. https:\/\/doi.org\/10.1016\/B978-0-443-22374-7.00019-0.","DOI":"10.1016\/B978-0-443-22374-7.00019-0"},{"key":"3204_CR42","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nnano.2007.223","volume":"2","author":"MA Dobrovolskaia","year":"2007","unstructured":"Dobrovolskaia MA, McNeil SE. Immunological properties of engineered nanomaterials. Nat Nanotechnol. 2007;2:469\u201378. https:\/\/doi.org\/10.1038\/nnano.2007.223.","journal-title":"Nat Nanotechnol"},{"key":"3204_CR43","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nm0398-321","volume":"4","author":"SA Rosenberg","year":"1998","unstructured":"Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998;4:321\u20137. https:\/\/doi.org\/10.1038\/nm0398-321.","journal-title":"Nat Med"},{"key":"3204_CR44","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13045-020-00916-z","volume":"13","author":"M Jiang","year":"2020","unstructured":"Jiang M, Chen P, Wang L, Li W, Chen B, Liu Y, et al. cGAS-STING, an important pathway in cancer immunotherapy. J Hematol Oncol. 2020;13:81. https:\/\/doi.org\/10.1186\/s13045-020-00916-z.","journal-title":"J Hematol Oncol"},{"key":"3204_CR45","doi-asserted-by":"publisher","first-page":"3745","DOI":"10.1038\/s41467-019-11730-8","volume":"10","author":"C Song","year":"2019","unstructured":"Song C, Phuengkham H, Kim YS, Dinh VV, Lee I, Shin IW, et al. Syringeable immunotherapeutic nanogel reshapes tumor microenvironment and prevents tumor metastasis and recurrence. Nat Commun. 2019;10:3745. https:\/\/doi.org\/10.1038\/s41467-019-11730-8.","journal-title":"Nat Commun"},{"key":"3204_CR46","doi-asserted-by":"publisher","first-page":"122766","DOI":"10.1016\/j.biomaterials.2024.122766","volume":"313","author":"L Wang","year":"2025","unstructured":"Wang L, Bi S, Li Z, Liao A, Li Y, Yang L, et al. Napabucasin deactivates STAT3 and promotes mitoxantrone-mediated cGAS-STING activation for hepatocellular carcinoma chemo-immunotherapy. Biomaterials. 2025;313:122766. https:\/\/doi.org\/10.1016\/j.biomaterials.2024.122766.","journal-title":"Biomaterials"},{"key":"3204_CR47","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ccell.2024.01.007","volume":"42","author":"X Yang","year":"2024","unstructured":"Yang X, Yang C, Zhang S, Geng H, Zhu AX, Bernards R, et al. Precision treatment in advanced hepatocellular carcinoma. Cancer Cell. 2024;42:180\u201397. https:\/\/doi.org\/10.1016\/j.ccell.2024.01.007.","journal-title":"Cancer Cell"},{"key":"3204_CR48","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1200\/JCO.2025.43.4_suppl.621","volume":"43","author":"JH Jaradat","year":"2025","unstructured":"Jaradat JH, Ilerhunmwuwa NP, Singh M, \u015eahin \u0130H, Saeed A. Evaluating immune cell abundance across hepatocellular carcinoma disease stages I\u2013III: findings from TCGA analysis. J Clin Oncol. 2025;43:621. https:\/\/doi.org\/10.1200\/JCO.2025.43.4_suppl.621.","journal-title":"J Clin Oncol"},{"key":"3204_CR49","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nrc2734","volume":"9","author":"H Yu","year":"2009","unstructured":"Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer. 2009;9:798\u2013809. https:\/\/doi.org\/10.1038\/nrc2734.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3204_CR50","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12964-025-02170-7","volume":"23","author":"X Liu","year":"2025","unstructured":"Liu X, Kang X, Kang H, Yan H. The immunosuppressive role of MDSCs in HCC: mechanisms and therapeutic opportunities. Cell Communication Signal. 2025;23(1):155.","journal-title":"Cell Communication Signal"},{"key":"3204_CR51","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1034\/j.1600-0528.2002.017408.x","volume":"174","author":"PA Knolle","year":"2000","unstructured":"Knolle PA, Gerken G. Local control of the immune response in the liver. Immunol Rev. 2000;174:21\u201334. https:\/\/doi.org\/10.1034\/j.1600-0528.2002.017408.x.","journal-title":"Immunol Rev"},{"issue":"3","key":"3204_CR52","first-page":"323","volume":"2","author":"X Li","year":"2023","unstructured":"Li X, Wang H, Chen Y, Li Z, Liu S, Guan W, Lin Y, Cao C, Zheng W, Wu J. Novel emerging nano-assisted anti-cancer strategies based on the STING pathway. Acta Materia Med. 2023;2(3):323\u201341.","journal-title":"Acta Materia Med"},{"key":"3204_CR53","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/s41401-020-0417-3","volume":"41","author":"WM Yin","year":"2020","unstructured":"Yin WM, Li YW, Gu YQ, Luo M. Nanoengineered targeting strategy for cancer immunotherapy. Acta Pharmacol Sin. 2020;41:902\u201310. https:\/\/doi.org\/10.1038\/s41401-020-0417-3.","journal-title":"Acta Pharmacol Sin"},{"key":"3204_CR54","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.4161\/cc.7.18.6672","volume":"7","author":"J Filmus","year":"2008","unstructured":"Filmus J, Capurro M. The role of glypican-3 in the regulation of body size and cancer. Cell Cycle. 2008;7:2787\u201390. https:\/\/doi.org\/10.4161\/cc.7.18.6672.","journal-title":"Cell Cycle"},{"key":"3204_CR55","doi-asserted-by":"publisher","first-page":"h988","DOI":"10.1136\/bmj.h988","volume":"350","author":"LH Butterfield","year":"2015","unstructured":"Butterfield LH. Cancer vaccines. BMJ. 2015;350:h988. https:\/\/doi.org\/10.1136\/bmj.h988.","journal-title":"BMJ"},{"key":"3204_CR56","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2217\/imt-2017-0154","volume":"10","author":"M Seifi-Alan","year":"2018","unstructured":"Seifi-Alan M, Shamsi R, Ghafouri-Fard S. Application of cancer-testis antigens in immunotherapy of hepatocellular carcinoma. Immunotherapy. 2018;10:411\u201321. https:\/\/doi.org\/10.2217\/imt-2017-0154.","journal-title":"Immunotherapy"},{"key":"3204_CR57","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41586-020-2056-8","volume":"579","author":"TD Wu","year":"2020","unstructured":"Wu TD, Madireddi S, de Almeida PE, Banchereau R, Chen YJ, Chitre AS, et al. Peripheral T cell expansion predicts tumour infiltration and clinical response. Nature. 2020;579:274\u20138. https:\/\/doi.org\/10.1038\/s41586-020-2056-8.","journal-title":"Nature"},{"key":"3204_CR58","doi-asserted-by":"publisher","first-page":"10","DOI":"10.54457\/DR.202402007","volume":"5","author":"X Kong","year":"2024","unstructured":"Kong X, Zhang Z, Tang H, Chen Y, Li J. Nanoparticles drug delivery system in targeted therapy of hepatocellular carcinoma. Dis Res. 2024;5:10\u20138. https:\/\/doi.org\/10.54457\/DR.202402007.","journal-title":"Dis Res"},{"key":"3204_CR59","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/20415990.2024.2435240","volume":"16","author":"J Patil","year":"2025","unstructured":"Patil J, Bhattacharya S, Saoji SD, Dande P. Cabozantinib-phospholipid complex for enhanced solubility, bioavailability, and reduced toxicity in liver cancer. Ther Deliv. 2025;16:25\u201341. https:\/\/doi.org\/10.1080\/20415990.2024.2435240.","journal-title":"Ther Deliv"},{"key":"3204_CR60","doi-asserted-by":"publisher","unstructured":"Song J, Zhu J, Jiang Y, Guo Y, Liu S, Qiao Y, et al. Advancements in immunotherapy for gastric cancer: unveiling the potential of immune checkpoint inhibitors and emerging strategies. Biochim Biophys Acta Rev Cancer. 2025;189277. https:\/\/doi.org\/10.1016\/j.bbcan.2025.189277.","DOI":"10.1016\/j.bbcan.2025.189277"},{"key":"3204_CR61","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3390\/cancers17030376","volume":"17","author":"I Aggeletopoulou","year":"2025","unstructured":"Aggeletopoulou I, Pantzios S, Triantos C. Personalized immunity: Neoantigen-based vaccines revolutionizing hepatocellular carcinoma treatment. Cancers. 2025;17:376. https:\/\/doi.org\/10.3390\/cancers17030376.","journal-title":"Cancers"},{"key":"3204_CR62","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ccell.2019.08.007","volume":"36","author":"L Ma","year":"2019","unstructured":"Ma L, Hernandez MO, Zhao Y, Mehta M, Tran B, Kelly M, et al. Tumor cell biodiversity drives microenvironmental reprogramming in liver cancer. Cancer Cell. 2019;36:418\u2013e306. https:\/\/doi.org\/10.1016\/j.ccell.2019.08.007.","journal-title":"Cancer Cell"},{"key":"3204_CR63","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, et al. An Immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547:217\u201321. https:\/\/doi.org\/10.1038\/nature22991.","journal-title":"Nature"},{"key":"3204_CR64","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41586-023-05787-1","volume":"615","author":"C Puig-Saus","year":"2023","unstructured":"Puig-Saus C, Sennino B, Peng S, Wang CL, Pan Z, Yuen B, et al. Neoantigen-targeted CD8\u2009+\u2009T cell responses with PD-1 Blockade therapy. Nature. 2023;615:697\u2013704. https:\/\/doi.org\/10.1038\/s41586-023-05787-1.","journal-title":"Nature"},{"key":"3204_CR65","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15:486\u201399. https:\/\/doi.org\/10.1038\/nri3862.","journal-title":"Nat Rev Immunol"},{"key":"3204_CR66","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s44342-024-00033-0","volume":"23","author":"M Shah","year":"2025","unstructured":"Shah M, Hussain M, Woo HG. Structural insights into antibody-based immunotherapy for hepatocellular carcinoma. Genomics Inf. 2025;23:367\u201381. https:\/\/doi.org\/10.1186\/s44342-024-00033-0.","journal-title":"Genomics Inf"},{"key":"3204_CR67","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1007\/s00262-008-0512-7","volume":"57","author":"B Seliger","year":"2008","unstructured":"Seliger B. Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. Cancer Immunol Immunother. 2008;57:1719\u201326. https:\/\/doi.org\/10.1007\/s00262-008-0512-7.","journal-title":"Cancer Immunol Immunother"},{"key":"3204_CR68","doi-asserted-by":"publisher","first-page":"122766","DOI":"10.1016\/j.biomaterials.2024.122766","volume":"313","author":"L Wang","year":"2025","unstructured":"Wang L, Bi S, Li Z, Liao A, Li Y, Yang L, Zhou X, Gao Y, Liu X, Zou Y, Zhang X. Napabucasin deactivates STAT3 and promotes mitoxantrone-mediated cGAS-STING activation for hepatocellular carcinoma chemo-immunotherapy. Biomaterials. 2025;313:122766.","journal-title":"Biomaterials"},{"key":"3204_CR69","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","volume":"74","author":"Y Zhu","year":"2014","unstructured":"Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, et al. CSF1\/CSF1R Blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014;74:5057\u201369. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-3723.","journal-title":"Cancer Res"},{"key":"3204_CR70","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41551-018-0236-8","volume":"2","author":"CB Rodell","year":"2018","unstructured":"Rodell CB, Arlauckas SP, Cuccarese MF, Garris CS, Li R, Ahmed MS, et al. TLR7\/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. Nat Biomed Eng. 2018;2:578\u201388. https:\/\/doi.org\/10.1038\/s41551-018-0236-8.","journal-title":"Nat Biomed Eng"},{"key":"3204_CR71","doi-asserted-by":"publisher","first-page":"4495","DOI":"10.1021\/acsnano.2c10352","volume":"17","author":"Z Deng","year":"2023","unstructured":"Deng Z, Xi M, Zhang C, Wu X, Li Q, Wang C, et al. Biomineralized MnO2 nanoplatforms mediated delivery of immune checkpoint inhibitors with STING pathway activation to potentiate cancer radio-immunotherapy. ACS Nano. 2023;17:4495\u2013506. https:\/\/doi.org\/10.1021\/acsnano.2c10352.","journal-title":"ACS Nano"},{"key":"3204_CR72","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","volume":"23","author":"T Yau","year":"2022","unstructured":"Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, et al. Nivolumab versus Sorafenib in advanced hepatocellular carcinoma (CheckMate 459): A randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23:77\u201390. https:\/\/doi.org\/10.1016\/S1470-2045(21)00604-5.","journal-title":"Lancet Oncol"},{"issue":"15","key":"3204_CR73","doi-asserted-by":"publisher","first-page":"5172","DOI":"10.1039\/D2CS00848C","volume":"52","author":"H Ren","year":"2023","unstructured":"Ren H, Jia W, Xie Y, Yu M, Chen Y. Adjuvant physiochemistry and advanced nanotechnology for vaccine development. Chem Soc Rev. 2023;52(15):5172\u2013254.","journal-title":"Chem Soc Rev"},{"key":"3204_CR74","doi-asserted-by":"publisher","first-page":"eadf4726","DOI":"10.1126\/sciimmunol.adf4726","volume":"10","author":"V Bhandarkar","year":"2025","unstructured":"Bhandarkar V, Dinter T, Spranger S. Architects of immunity: how dendritic cells shape CD8\u2009+\u2009T cell fate in cancer. Sci Immunol. 2025;10:eadf4726. https:\/\/doi.org\/10.1126\/sciimmunol.adf4726.","journal-title":"Sci Immunol"},{"key":"3204_CR75","doi-asserted-by":"publisher","first-page":"2006000","DOI":"10.1002\/smll.202006000","volume":"17","author":"L Qin","year":"2021","unstructured":"Qin L, Zhang H, Zhou Y, Umeshappa CS, Gao H. Nanovaccine-based strategies to overcome challenges in the whole vaccination cascade for tumor immunotherapy. Small. 2021;17:2006000. https:\/\/doi.org\/10.1002\/smll.202006000.","journal-title":"Small"},{"key":"3204_CR76","doi-asserted-by":"publisher","first-page":"11109","DOI":"10.1021\/acs.chemrev.5b00109","volume":"115","author":"DJ Irvine","year":"2015","unstructured":"Irvine DJ, Hanson MC, Rakhra K, Tokatlian T. Synthetic nanoparticles for vaccines and immunotherapy. Chem Rev. 2015;115:11109\u201346. https:\/\/doi.org\/10.1021\/acs.chemrev.5b00109.","journal-title":"Chem Rev"},{"key":"3204_CR77","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nri3488","volume":"13","author":"DM Smith","year":"2013","unstructured":"Smith DM, Simon JK, Baker JR Jr. Applications of nanotechnology for immunology. Nat Rev Immunol. 2013;13:592\u2013605. https:\/\/doi.org\/10.1038\/nri3488.","journal-title":"Nat Rev Immunol"},{"key":"3204_CR78","doi-asserted-by":"publisher","first-page":"4c17279","DOI":"10.1021\/acsnano.4c17279","volume":"19","author":"H Zhu","year":"2025","unstructured":"Zhu H, Xu C, Geng Y, Shen Y, Qiu N. Endoplasmic reticulum-targeted polymer-manganese nanocomplexes for tumor immunotherapy. ACS Nano. 2025;19:4c17279. https:\/\/doi.org\/10.1021\/acsnano.4c17279.","journal-title":"ACS Nano"},{"key":"3204_CR79","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1186\/s12951-024-02859-w","volume":"22","author":"X Meng","year":"2024","unstructured":"Meng X, Shen Y, Zhao H, Lu X, Wang Z, Zhao Y. Redox-manipulating nanocarriers for anticancer drug delivery: A systematic review. J Nanobiotechnol. 2024;22:587. https:\/\/doi.org\/10.1186\/s12951-024-02859-w.","journal-title":"J Nanobiotechnol"},{"key":"3204_CR80","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20:101\u201324. https:\/\/doi.org\/10.1038\/s41573-020-0090-8.","journal-title":"Nat Rev Drug Discov"},{"issue":"48","key":"3204_CR81","doi-asserted-by":"publisher","first-page":"2409914","DOI":"10.1002\/adma.202409914","volume":"36","author":"SM Jin","year":"2024","unstructured":"Jin SM, Cho JH, Gwak Y, Park SH, Choi K, Choi JH, Shin HS, Hong J, Bae YS, Ju J, Shin M. Transformable Gel-to\u2010Nanovaccine enhances cancer immunotherapy via Metronomic\u2010Like Immunomodulation and Collagen\u2010Mediated paracortex delivery. Adv Mater. 2024;36(48):2409914.","journal-title":"Adv Mater"},{"key":"3204_CR82","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.3390\/pharmaceutics15071868","volume":"15","author":"H Huang","year":"2023","unstructured":"Huang H, Liu R, Yang J, Dai J, Fan S, Pi J, et al. Gold nanoparticles: construction for drug delivery and application in cancer immunotherapy. Pharmaceutics. 2023;15:1868. https:\/\/doi.org\/10.3390\/pharmaceutics15071868.","journal-title":"Pharmaceutics"},{"key":"3204_CR83","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.3389\/fimmu.2018.02224","volume":"9","author":"R Pati","year":"2018","unstructured":"Pati R, Shevtsov M, Sonawane A. Nanoparticle vaccines against infectious diseases. Front Immunol. 2018;9:2224. https:\/\/doi.org\/10.3389\/fimmu.2018.02224.","journal-title":"Front Immunol"},{"key":"3204_CR84","doi-asserted-by":"publisher","first-page":"20241550","DOI":"10.54254\/2753-8818\/64\/20241550","volume":"64","author":"X You","year":"2024","unstructured":"You X. Functionalized gold nanoparticles serve as nanovaccine to boost immune protection for cancer. Theor Nat Sci. 2024;64:20241550. https:\/\/doi.org\/10.54254\/2753-8818\/64\/20241550.","journal-title":"Theor Nat Sci"},{"key":"3204_CR85","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/ni.3123","volume":"16","author":"A Iwasaki","year":"2015","unstructured":"Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune system. Nat Immunol. 2015;16:343\u201353. https:\/\/doi.org\/10.1038\/ni.3123.","journal-title":"Nat Immunol"},{"key":"3204_CR86","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/ni.1863","volume":"11","author":"T Kawai","year":"2010","unstructured":"Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11:373\u201384. https:\/\/doi.org\/10.1038\/ni.1863.","journal-title":"Nat Immunol"},{"key":"3204_CR87","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/nnano.2007.387","volume":"2","author":"D Peer","year":"2007","unstructured":"Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2:751\u201360. https:\/\/doi.org\/10.1038\/nnano.2007.387.","journal-title":"Nat Nanotechnol"},{"issue":"7","key":"3204_CR88","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.7150\/thno.107856","volume":"15","author":"Y Lin","year":"2025","unstructured":"Lin Y, Lin P, Xu R, Chen X, Lu Y, Zheng J, Zheng Y, Zhou Z, Mai Z, Zhao X, Cui L. Nanovaccines empowering CD8\u2009+\u2009T cells: a precision strategy to enhance cancer immunotherapy. Theranostics. 2025;15(7):3098.","journal-title":"Theranostics"},{"key":"3204_CR89","doi-asserted-by":"publisher","first-page":"7335","DOI":"10.4049\/jimmunol.176.12.7335","volume":"176","author":"K Zaks","year":"2006","unstructured":"Zaks K, Jordan M, Guth A, Sellins K, Kedl R, Izzo A, et al. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J Immunol. 2006;176:7335\u201345. https:\/\/doi.org\/10.4049\/jimmunol.176.12.7335.","journal-title":"J Immunol"},{"key":"3204_CR90","doi-asserted-by":"publisher","first-page":"5317","DOI":"10.1158\/0008-5472.CAN-04-3921","volume":"65","author":"JF Kukowska-Latallo","year":"2005","unstructured":"Kukowska-Latallo JF, Candido KA, Cao Z, Nigavekar SS, Majoros IJ, Thomas TP, et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res. 2005;65:5317\u201324. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-3921.","journal-title":"Cancer Res"},{"key":"3204_CR91","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ijpharm.2005.03.035","volume":"298","author":"C Foged","year":"2005","unstructured":"Foged C, Brodin B, Frokjaer S, Sundblad A. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int J Pharm. 2005;298:315\u201322. https:\/\/doi.org\/10.1016\/j.ijpharm.2005.03.035.","journal-title":"Int J Pharm"},{"key":"3204_CR92","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.4049\/jimmunol.173.5.3148","volume":"173","author":"T Fifis","year":"2004","unstructured":"Fifis T, Gamvrellis A, Crimeen-Irwin B, Pietersz GA, Li J, Mottram PL, et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol. 2004;173:3148\u201354. https:\/\/doi.org\/10.4049\/jimmunol.173.5.3148.","journal-title":"J Immunol"},{"key":"3204_CR93","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41541-024-01056-y","volume":"10","author":"LAM Cornelissen","year":"2025","unstructured":"Huis in \u2019t Veld LGM, Cornelissen LAM, van den Bogaard L, Ansems M, Ho NI, Adema GJ. Saponin-based adjuvant uptake and induction of antigen cross-presentation by CD11b\u2009+\u2009dendritic cells and macrophages. NPJ Vaccines. 2025;10:15. https:\/\/doi.org\/10.1038\/s41541-024-01056-y.","journal-title":"NPJ Vaccines"},{"key":"3204_CR94","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/32588","volume":"392","author":"J Banchereau","year":"1998","unstructured":"Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245\u201352. https:\/\/doi.org\/10.1038\/32588.","journal-title":"Nature"},{"key":"3204_CR95","doi-asserted-by":"publisher","first-page":"622","DOI":"10.3390\/cancers14030622","volume":"14","author":"VV Veselov","year":"2022","unstructured":"Veselov VV, Nosyrev AE, Jicsinszky L, Alyautdin RN, Cravotto G. Targeted delivery methods for anticancer drugs. Cancers (Basel). 2022;14:622. https:\/\/doi.org\/10.3390\/cancers14030622.","journal-title":"Cancers (Basel)"},{"key":"3204_CR96","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.0017","author":"GC Giudice","year":"2025","unstructured":"Giudice GC, Beckermann KE, Do Amaral PS, Rini BI. Immunotherapy strategies after immune checkpoint inhibitor exposure in renal cell carcinoma: A review. JAMA Oncol. 2025. https:\/\/doi.org\/10.1001\/jamaoncol.2025.0017. [Epub ahead of print].","journal-title":"JAMA Oncol"},{"key":"3204_CR97","doi-asserted-by":"publisher","unstructured":"Wu Y. Developing lipid-coated calcium carbonate\/phosphate hybrid nanoparticles as a gene\/drug co-delivery platform for combined cancer therapy [PhD thesis]. Brisbane: The University of Queensland; 2019. https:\/\/doi.org\/10.14264\/uql.2020.5","DOI":"10.14264\/uql.2020.5"},{"key":"3204_CR98","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","volume":"16","author":"JD Yang","year":"2019","unstructured":"Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: Trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589\u2013604. https:\/\/doi.org\/10.1038\/s41575-019-0186-y.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3204_CR99","doi-asserted-by":"publisher","first-page":"2450120","DOI":"10.1080\/21645515.2025.2450120","volume":"21","author":"J Tica","year":"2025","unstructured":"Tica J, Rezelj VV, Baron B, van Paassen V, Zaidman J, Fairlie L, et al. Safety and immunogenicity of Ad26.COV2.S in adolescents: phase 2 randomized clinical trial. Hum Vaccin Immunother. 2025;21:2450120. https:\/\/doi.org\/10.1080\/21645515.2025.2450120.","journal-title":"Hum Vaccin Immunother"},{"key":"3204_CR100","doi-asserted-by":"publisher","first-page":"2448405","DOI":"10.1080\/21645515.2024.2448405","volume":"21","author":"S Jia","year":"2025","unstructured":"Jia S, Shao C, Cheng X, Pan H, Wang Z, Xia Y, et al. Immunogenicity and safety of a COVID-19 DNA vaccine in healthy adults and elderly: A randomized, observer-blind, placebo-controlled phase 2 trial. Hum Vaccin Immunother. 2025;21:2448405. https:\/\/doi.org\/10.1080\/21645515.2024.2448405.","journal-title":"Hum Vaccin Immunother"},{"key":"3204_CR101","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1056\/NEJM198010093031501","volume":"303","author":"W Szmuness","year":"1980","unstructured":"Szmuness W, Stevens CE, Harley EJ, Zang EA, Oleszko WR, William DC, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the united States. N Engl J Med. 1980;303:833\u201341. https:\/\/doi.org\/10.1056\/NEJM198010093031501.","journal-title":"N Engl J Med"},{"key":"3204_CR102","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/PPO.0b013e318233e5b2","volume":"17","author":"CL Slingluff Jr","year":"2011","unstructured":"Slingluff CL Jr. The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination? Cancer J. 2011;17:343\u201350. https:\/\/doi.org\/10.1097\/PPO.0b013e318233e5b2.","journal-title":"Cancer J"},{"key":"3204_CR103","doi-asserted-by":"publisher","unstructured":"Tounekti O, Prior S, Wassmer S, Xu J, Wong A, Fang X, et al. 2024 white paper on recent issues in bioanalysis. Bioanalysis. 2024;1\u201345. https:\/\/doi.org\/10.1080\/17576180.2024.2439229.","DOI":"10.1080\/17576180.2024.2439229"},{"key":"3204_CR104","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1200\/JCO.2025.43.4_suppl.602","volume":"43","author":"GM O\u2019Kane","year":"2025","unstructured":"O\u2019Kane GM, Mesci A, Chen EX, Bocaya CM, Jang R, Wang BX, et al. Pembrolizumab and stereotactic radiotherapy combined in subjects with advanced HCC: A phase II study (PEMRAD). J Clin Oncol. 2025;43:602. https:\/\/doi.org\/10.1200\/JCO.2025.43.4_suppl.602.","journal-title":"J Clin Oncol"},{"key":"3204_CR105","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1200\/JCO.2025.43.4_suppl.617","volume":"43","author":"A Grahovac","year":"2025","unstructured":"Grahovac A, Sandow T, Mizrahi J, Du L, Vallejo-Calzada R, Gimenez J, et al. Safety, efficacy, and outcomes of 90-yttrium radioembolization in combination with immune checkpoint inhibitors in non-surgical hepatocellular carcinoma. J Clin Oncol. 2025;43:617. https:\/\/doi.org\/10.1200\/JCO.2025.43.4_suppl.617.","journal-title":"J Clin Oncol"},{"key":"3204_CR106","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1158\/1078-0432.728.11.2","volume":"11","author":"S Demaria","year":"2005","unstructured":"Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP, et al. Immune-mediated Inhibition of metastases after treatment with local radiation and CTLA-4 Blockade in a mouse model of breast cancer. Clin Cancer Res. 2005;11:728\u201334. PMID:15701862.","journal-title":"Clin Cancer Res"},{"key":"3204_CR107","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nrd3626","volume":"11","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov. 2012;11:215\u201333. https:\/\/doi.org\/10.1038\/nrd3626.","journal-title":"Nat Rev Drug Discov"},{"key":"3204_CR108","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3390\/pharmaceutics17030375","volume":"17","author":"M El-Tanani","year":"2025","unstructured":"El-Tanani M, Satyam SM, Rabbani SA, El-Tanani Y, Aljabali AA, Al Faouri I, et al. Revolutionizing drug delivery: the impact of advanced materials science and technology on precision medicine. Pharmaceutics. 2025;17:375. https:\/\/doi.org\/10.3390\/pharmaceutics17030375.","journal-title":"Pharmaceutics"},{"key":"3204_CR109","doi-asserted-by":"publisher","first-page":"0093","DOI":"10.1108\/ijlss-05-2024-0093","volume":"16","author":"R Gurumurthy","year":"2025","unstructured":"Gurumurthy R, Pereira A, Laux C. Optimizing high-mix, high-volume advanced healthcare manufacturing: implementation and impact of the production wheel framework. Int J Lean Six Sigma. 2025;16:0093. https:\/\/doi.org\/10.1108\/ijlss-05-2024-0093.","journal-title":"Int J Lean Six Sigma"},{"key":"3204_CR110","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3390\/nano8050311","volume":"8","author":"S Mulhopt","year":"2018","unstructured":"Mulhopt S, Diabat\u00e9 S, Dilger M, Adelhelm C, Anderlohr C, Bergfeldt T, et al. Characterization of nanoparticle batch-to-batch variability. Nanomaterials (Basel). 2018;8:311. https:\/\/doi.org\/10.3390\/nano8050311.","journal-title":"Nanomaterials (Basel)"},{"key":"3204_CR111","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1200\/JCO.2025.43.4_suppl.613","volume":"43","author":"B Pasche","year":"2025","unstructured":"Pasche B, Benson AB, Kudo M, Shields AF, Jimenez H, Azar I, et al. Development and regulatory approval of a new systemic targeted therapy for advanced hepatocellular carcinoma. J Clin Oncol. 2025;43:613. https:\/\/doi.org\/10.1200\/JCO.2025.43.4_suppl.613.","journal-title":"J Clin Oncol"},{"key":"3204_CR112","volume-title":"Nanotechnology: A report of the U.S. Food and drug administration nanotechnology task force","author":"FDA Nanotechnology Task Force","year":"2007","unstructured":"FDA Nanotechnology Task Force. Nanotechnology: A report of the U.S. Food and drug administration nanotechnology task force. Silver Spring (MD): U.S. Food and Drug Administration; 2007."},{"key":"3204_CR113","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1200\/JCO.2025.43.4_suppl.562","volume":"43","author":"H Zhiyong","year":"2025","unstructured":"Zhiyong H, Jonas E, Liu L, Smith M, Soliman HE, Li J, et al. A global comparative study on MDT practices in the management of hepatocellular carcinoma in high-income countries (HICs) and low- and middle-income countries (LMICs). J Clin Oncol. 2025;43:562. https:\/\/doi.org\/10.1200\/JCO.2025.43.4_suppl.562.","journal-title":"J Clin Oncol"},{"key":"3204_CR114","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1001294.","journal-title":"N Engl J Med"},{"issue":"1","key":"3204_CR115","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12943-024-02214-5","volume":"24","author":"M Wang","year":"2025","unstructured":"Wang M, Yu F, Zhang Y. Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges. Molecular Cancer. 2025; Jan 18;24(1):26. https:\/\/doi.org\/10.1186\/s12943-024-02214-5.","journal-title":"Molecular Cancer"},{"key":"3204_CR116","doi-asserted-by":"publisher","first-page":"21782","DOI":"10.1039\/C9NR05475H","volume":"11","author":"J Yang","year":"2019","unstructured":"Yang J, Arya S, Lung P, Lin Q, Huang J, Li Q. Hybrid nanovaccine for the co-delivery of the mRNA antigen and adjuvant. Nanoscale. 2019;11:21782\u20139. https:\/\/doi.org\/10.1039\/C9NR05475H.","journal-title":"Nanoscale"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03204-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-03204-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03204-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T14:46:17Z","timestamp":1770389177000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-03204-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":116,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["3204"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-03204-3","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]},"assertion":[{"value":"1 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This article is a review and does not involve studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"90"}}